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Abstract
Background: Nonalcoholic fatty liver disease affects about 24% of the world’s population and may progress to
nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). While more common in those
that are obese, NASH-HCC can develop in lean individuals. The mechanisms by which HCC develops and the role of
epigenetic changes in the context of obesity and normal weight are not well understood.
Methods: In this study, we used previously generated mouse models of lean and obese HCC using a choline deficient/high trans-fat/fructose/cholesterol diet and a choline supplemented/high trans-fat/fructose/cholesterol diet,
respectively, to evaluate methylation differences in HCC progression in lean versus obese mice. Differentially methylated regions were determined using reduced representation bisulfite sequencing.
Results: A larger number of differentially methylated regions (DMRs) were seen in NASH-HCC progression in the
obese mice compared to the non-obese mice. No overlap existed in the DMRs with the largest methylation differences between the two models. In lean NASH-HCC, methylation differences were seen in genes involved with cancer
progression and prognosis (including HCC), such as CHCHD2, FSCN1, and ZDHHC12, and lipid metabolism, including
PNPLA6 and LDLRAP1. In obese NASH- HCC, methylation differences were seen in genes known to be associated with
HCC, including RNF217, GJA8, PTPRE, PSAPL1, and LRRC8D. Genes involved in Wnt-signaling pathways were enriched
in hypomethylated DMRs in the obese NASH-HCC.
Conclusions: These data suggest that differential methylation may play a role in hepatocarcinogenesis in lean versus
obese NASH. Hypomethylation of Wnt signaling pathway-related genes in obese mice may drive progression of HCC,
while progression of HCC in lean mice may be driven through other signaling pathways, including lipid metabolism.
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Background
Nonalcoholic fatty liver disease (NAFLD) affects approximately 24% of the world’s population [1]. NAFLD encompasses a spectrum of diseases characterized by fat in the
liver that may progress to nonalcoholic steatohepatitis
(NASH) with inflammation and fibrosis and ultimately to
cirrhosis, which results in an increased risk of developing
hepatocellular carcinoma (HCC) [2]. Treatment options
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for advanced stage HCC are limited, so understanding
the development of HCC may identify opportunities for
drug interventions or opportunities for primary prevention efforts [3]. Knowledge of the role of diet in the development of HCC has great importance for understanding
the mechanism by which NASH progresses to HCC.
While often associated with obesity, NAFLD may
develop among lean individuals as well, especially among
those that are of normal weight but metabolically obese
[1]. The exact causes of lean NAFLD are not clear, but
those with lean NAFLD are less likely to have obesityrelated co-morbidities [4, 5]. The role of diet in the progression of NASH to HCC is not well understood. The
complex pathways involved in NASH-related HCC likely
involve genetic and epigenetic factors [2]. Differential
methylation patterns of HCC may be useful in developing
pharmacological interventions, since DNA methylation is
reversible and hence susceptible to intervention [6].
It was previously found that the remodeling of DNA
methylation occurs at genes in patients with NASH and
fibrosis, suggesting that epigenetic signatures may be
a possible biomarker for severity of disease [1]. Previous studies have identified potential causal relationships
between epigenetic changes and liver carcinogenesis [6].
In HCC, hypomethylation has been found with transcriptional enhancers and hypermethylation has been found
with promoter-associated CGIs and cis-regulatory elements [6]. Additionally, lower expression of phosphatidylethanolamine N-methyltransferase (PEMT) was found
in individuals with lean NASH, which could be implicated in its progression [5].
To date, only a few studies have investigated the role of
epigenetic changes in the progression of NASH-related
HCC in lean versus obese individuals. In this study we
used previously developed novel models of lean and
obese NASH-HCC in mice using choline deficient (CD)
and choline supplemented (CS) high trans-fat/fructose/
cholesterol diets to examine differences in DNA methylation during the progression of NASH to HCC as well as
differences of DNA methylation in HCC progression in
lean versus obese mice.

Methods
Animals and experimental diets

This study was approved by the Institutional Animal
Care and Use Committee at the University of Nebraska
Medical Center (Protocol #: 17–018) and was also conducted in compliance with the ARRIVE guidelines. Male
(n = 103) C57BL/6 N mice (Charles River Laboratories)
were allowed to acclimate and housed as previously
described beginning at 3 weeks of age [7]. 30 males were
fed a choline supplemented, high trans-fat, fructose, and
cholesterol diet (CS-HFFC; D18091706), 38 males were
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fed a choline deficient, high trans-fat, fructose, and cholesterol diet (CD-HFFC; D17071001), and 35 males were
fed a low-fat control diet (CON; D16120211; Research
Diets, New Brunswick, New Jersey). The estimated HCC
penetrance from our previous work was used to determine this sample size [7]. The consumption of food was
monitored, and the mice were regularly weighed and husbandry checks were performed as previously described
[7].
Histological evaluation

All mice were monitored until the endpoint of the study
(64 weeks of age). Any mice showing signs of poor health
were euthanized per institutional ethical guidelines by
CO2 inhalation. After harvesting tissues for analysis,
exsanguination was done to confirm death. A cardiac
puncture was performed to collect blood right after
euthanasia was performed. Livers were excised, weighed,
and observed grossly for the appearance of nodules.
The tissue samples were snap frozen in liquid nitrogen
and then stored at − 80 °C. The remaining tissues were
fixed in 10% formalin for 2 hours and paraffin embedded at the Tissue Sciences Facilities at the University of
Nebraska Medical Center. Hematoxylin and Eosin (H&E)
and Masson-Trichome were used to stain tissue sections.
An additional reticulin stain was added at necropsy. An
experienced pathologist blindly evaluated the stained
sections, scoring the sections for steatosis, ballooning,
and inflammation to determine the presence of NAFLD
and NASH [8]. The stained liver sections were also evaluated for the presence of regenerative nodules, dysplastic
nodules, and hepatocellular carcinomas as previously
described [7].
DNA extraction and RRBS

Forty samples were selected for analysis: normal liver tissue from 6 controls, NASH tissue from 4 CD-HFFC fed
mice, dysplastic tissue from 7 CD-HFFC fed mice, HCC
tissue from 7 CD-HFFC fed mice, NASH tissue from 2
CS-HFFC fed mice, dysplastic tissue from 8 CS-HFFC fed
mice, and HCC tissue from 6 CS-HFFC fed mice. DNA
was isolated from 25 mg of snap-frozen liver tissue using
the Qiagen DNeasy blood and tissue kit (Qiagen, Germantown, MD). Genome wide DNA methylome analyses
were carried out on DNA samples (400-500 ng) using the
Diagenode Inc. (Denville, NJ) Premium Reduced Representation Bisulfite Sequencing (RRBS) kit on mouse
samples. DNA concentration of the samples was analyzed using the Qubit® dsDNA Assay Kit (Thermo Fisher
Scientific) and DNA quality was assessed using the
Fragment Analyzer™ and the DNF-488 High Sensitivity
genomic DNA Analysis Kit (Agilent).
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DNA methylation data analysis

The output from RRBS was read into the methylKit
(v1.16.1) package in R (v4.0.3) and analyzed by the Bioinformatics and Systems Biology Core at the University
of Nebraska Medical Center [9]. Logistic regression
tests were used for the differential methylation analyses and the sliding linear model (SLIM) method was
used for multiple testing adjustment on 15 comparisons
[10]. Generated q-values were used for representing the
adjusted p-values. Significance levels were determined
by the criteria q < 0.01 and percent methylation differences larger than 25%.
Annotation and functional pathway analysis

MethylKit was used to annotate the differentially
methylated regions to include the distance to the corresponding gene and gene ID. UniProt and Reference
sequence (RefSeq) were used to identify gene names
and function for significantly differentially methylated
regions [11, 12]. Gene Ontology enrichment analysis was done on the differentially methylated regions
between the choline deficient and choline supplemented HCC samples and between HCC and NASH in
both models to find the molecular function of regions
that are over- or under-represented in the sample
[13–15].

Results
Characterization of differentially methylated regions

Differentially methylated regions between each comparison (diet or disease stage) were categorized as
occurring either in CpG islands, shores, or other
regions (regions greater than 2 kb from CpG islands).
Among all comparisons shown in Fig. 1, the majority
of DMRs occurred in regions other than CpG islands
and shores. In the choline deficient model, there were
an increasing proportion of DMRs in CpG islands
through the progression of HCC and decreasing DMRs
in the other regions (Fig. 1A-C). In the choline supplemented model, there was a decreasing proportion of
DMRs in CpG islands and an increasing proportion of
DMRs in the other regions through the progression of
HCC (Fig. 1D-F). No uniform pattern of DMRs by gene
region was seen between the choline deficient and supplemented models at the NASH, dysplastic, and HCC
stages.
The proportion of DMRs by methylation loci (promoter, exon, intron, and intergenic regions) are shown
in Fig. 2. Similar patterns were observed across the
progression of HCC in the choline deficient and supplemented models. Between the comparisons of the
two diet models at each stage (Fig. 2G-I), the largest
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difference was seen in the proportion of DMRs in intergenic regions between the NASH and dysplastic stages,
with the latter showing a larger proportion of DMRs in
intergenic regions.
Figure 3 shows the number of differentially methylated regions per comparison, as well as the proportion
of hypermethylated and hypomethylated regions per
each comparison. In both diet models, the largest number of DMRs was seen between NASH and the controls;
the lowest number of DMRs was seen between HCC and
the dysplastic stage (Supplemental File 1). Among the
disease stage progression, there was a higher number of
DMRs among the choline supplemented model than the
choline deficient model, except for the HCC vs Dysplastic Nodules comparison. The proportion of DMRs that
were hypermethylated increased throughout the HCC
progression in both models, even though the number of
hypermethylated regions decreased with tumor progression. In the final three comparisons in Fig. 3 that compare
the stages between the two diet models, the highest number of DMRs was seen at the NASH stage. Compared to
the choline deficient model, there was a greater proportion of hypomethylated DMRs in the choline supplemented model in the NASH, dysplastic, and HCC stages.
Genomic distribution of DMRs

There were higher numbers of differentially methylated
regions in the progression of HCC in the choline-supplemented model (Fig. 4D-F, Supplemental File 1) compared
to the choline-deficient model (Fig. 4A-C) for each chromosome. While the numbers of DMRs were different, the
overall pattern per chromosome was similar in both diet
models. The proportion of DMRs that were hypermethylated was higher in the choline-supplemented model.
Comparing each stage of progression between the two
models, there was a greater proportion of hypomethylation per chromosome in the dysplastic and HCC stages
compared to NASH (Fig. 4G-I, Supplemental File 1).
Genes potentially modified by hyper/hypomethylation
in the progression of HCC

Comparing HCC and NASH in the CD and CS models,
a greater proportion of DMRs were in CpG islands and
promoter regions in the CS model; while there was significantly more DMRs in the CS model compared to the
CD model, the proportion of DMRs per chromosome
was similar (Supplemental Fig. 1). The top ten differentially hypermethylated and hypomethylated regions
with the greatest percent methylation differences
between CD HCC and NASH are presented in Table 1.
The regions with the largest percent methylation difference were a mix of hypermethylated and hypomethylated regions; the majority were outside of CpG islands
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Fig. 1 Percentages of CpG categories (islands, shores, or other) for significant differential DNA methylation loci. A. CD: NASH vs. Control. B. CD: Dysp
vs. NASH C. CD: HCC vs. NASH. D. CS: NASH vs Control. E. CS: Dysp vs. NASH F. CS: HCC vs. Dysp. G. CD NASH vs. CS NASH. H. CD Dysp. vs. CS Dysp. I.
CD HCC vs. CS HCC

and shores and were found mainly in exons or introns.
Within the CD model, several of the largest differentially methylated regions are in genes involved in lipid
metabolism (PNPLA6 and LDLRAP1), transcription
(CHCHD2), and Wnt signaling pathways (JADE1),
and cell migration and binding (TMEM88b, MYO5b,

FSNC1, and ZDHHC12) [11, 12]. The top ten differentially hypermethylated and hypomethylated regions
between CS HCC and NASH are presented in Table 2.
The percent methylation difference was larger among
the hypermethylated regions. There was no overlap in
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Fig. 2 Percentages of gene structure categories for significant differential DNA methylation loci. A. CD: NASH vs. Control. B. CD: Dysp vs. NASH C.
CD: HCC vs. NASH. D. CS: NASH vs Control. E. CS: Dysp vs. NASH F. CS: HCC vs. Dysp. G. CD NASH vs. CS NASH. H. CD Dysp vs. CS Dysp. I. CD HCC vs.
CS HCC

the regions with the highest percent methylation difference between HCC and NASH in the choline deficient
and supplemented models. DMRs were located mostly
outside of CpG islands and shores and were found in
introns and exons. The percent methylation differences
between HCC and NASH were higher in the CS model
(Table 2) than in the CD model (Table 1). Within the
CS model, the significantly differentially methylated
regions are found in genes involved in ion channels
(GJA8, KCNQ5, and LRRC8D), cell cycle regulation
(PTPRE and RNF123), and cell signaling pathways
(RNF217), including Wnt signaling (SOSTDC1) [11,
12]. Four of the differentially methylated regions were
in genes previously found to be associated with obesity,

metabolic regulation, and glycemic control (LRRC8D,
SOSTCD1, MORN3, and MCF2) [16–19].
Differences in methylation patterns of hepatocellular
carcinoma in lean and obese mice

Table 3 shows the top 10 differentially hypermethylated
and hypomethylated regions between HCC in the CD
model and HCC in the CS model. All but one of the top
10 overall regions with the highest percent difference in
methylation were hypomethylation, indicating that there
was a greater degree of methylation in the choline supplemented model HCC compared to the choline deficient
model. Of the hypermethylated regions, half were in CpG
islands and shores. Differential methylation was found
mostly in exons and introns. The corresponding genes
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Fig. 3 Number of differentially methylated regions by comparison

are involved in physiological process including cell signaling pathways, catabolic processes, and protein translation [11, 12]. Five hypermethylated regions were in genes
previously associated with cancer (TRAP1, SLC38A3,
CHRM1, EDN2, and PROX1), while six hypomethylated
regions were in genes previously associated with cancer (NUMBL, ALDH1B1, FTCD, FASTKD2, FAM96A,
and ARHGAP15) [20–30]. Five differentially methylated
regions were in genes previously found to be associated with obesity and altered metabolic states (TRAP1,
SLC38A3, PROX1, ALDH1B1, and FAM96A) [31–35].

included neuropeptide receptor activity, voltage-gated
potassium channel activity, transcription repressor activity, and signaling receptor activator activity. Additionally,
of the hypomethylated regions in HCC versus NASH, the
molecular functions of Wnt-protein binding and frizzled
binding were found to be enriched in the choline supplemented model, but not the choline deficient model
(Table 5). These different functional activities of differentially methylated regions may be involved in pathways
associated with the progression of HCC from NASH in
the context of lean and obese mice.

Functional analyses

Discussion
In this work, we demonstrated that significant differential
methylation exists in the progression of NASH-HCC in
the context of obesity (through choline supplementation)
and non-obesity (through choline deficiency) in mice fed
a high fat/fructose/cholesterol diet (Fig. 5). Larger numbers of DMRs were found between HCC and NASH in
the obese mice (41,979) compared to the non-obese mice
(11,104). In both models, the largest number of DMRs
were seen at the beginning stages of disease progression
(in NASH and dysplasia) and the proportion of DMRs

Gene Ontology enrichment analysis was performed on
the genes indicated as having a 25% or greater methylation difference in HCC versus NASH in both the choline
deficient and choline supplemented models. The DMRs
in both comparisons shared some functions, including
transcription activation and DNA binding in transcription (Table 4). Functions specific to the DMRs of the
choline deficient model of HCC progression included
hormone binding and calcium ion binding. Functions
specific to the DMRs of the choline supplemented model
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Fig. 4 Number of differentially methylated regions per chromosome. A. CD: NASH vs. Control. B. CD: Dysp vs. NASH C. CD: HCC vs. NASH. D. CS:
NASH vs Control. E. CS: Dysp vs. NASH F. CS: HCC vs. Dysp. G. CD NASH vs. CS NASH. H. CD Dysp vs. CS Dysp. I. CD HCC vs. CS HCC

that were hypermethylated increased with progression.
DNA methylation has previously been implicated in carcinogenesis; previous studies have identified differential
methylation in NASH-related HCC in both mice and
humans [36, 37]. Global hypomethylation is common
in carcinogenesis, with numerous methylation changes
occurring early in tumor progression [38]. The increased
number of DMRs and hypermethylation in the obese
mice may be driven by dietary choline, which is involved
in one-carbon metabolism in methylation [39]. Additionally, our previous work found that mice with HCC in the
context of obesity had higher plasma fasting glucose and
cholesterol levels than lean mice with HCC [40]; differences in glucose levels may contribute to the differential
methylation patterns identified, which is in line with previous work that found glucose levels were associated with
CpG methylation levels [41].
In the choline deficient model, significant hypermethylation of CHCHD2 (within an exon) and FSCN1 was seen.
Overexpression of both of these genes has been found to

be associated with HCC and found to be an indicator of
poor prognosis [42–44]. Our previous work identified
faster progression of HCC and worse survival in the choline deficient model; the role of these genes in carcinogenesis may depend on the stage of progression and site
of methylation. Significant differential methylation was
also found in exons of two genes involved in lipid metabolism, PNPLA6 (within a CpG shore) and LDLRAP1 [11].
In the choline supplemented model, significant hypermethylation of RNF217 was found, which has also been
seen with alcohol-related HCC in humans [45]. RNF217
is involved in process of ubiquitination [11]. Differential
methylation was also seen in genes previously identified
as tumor suppressor genes and oncogenes, including
KCNQ5, PTPRE, and SOSTDC1 [46–48]. Additionally,
hypermethylation was found in GJA8 (within an exon)
and hypomethylation was found in PSAPL1 and LRRC8D
(within introns); these three genes have all been found
to be associated with hepatocarcinogenesis [49–51].
Increased methylation of MORN3 and decreased
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Table 1 Top 10 hypermethylated and hypomethylated regions between HCC and NASH in the choline deficient model
Chromosome
Hypermethylation

Hypomethylation

Start

End

Q-value

Methylation
difference (%)

Gene

CpG Category

Gene Structure

Chr 8

3517616

3517616

1.65E-48

76.2212

PNPLA6

Shore

Exon

Chr 17

32105855

32105855

8.63E-47

68.636

–

Other

–

Chr 11

99645764

99645764

5.30E-74

67.33949

KRTAP4–7

Other

–

Chr 5

129557719

129557719

4.11E-59

65.9518

CHCHD2

Other

Exon

Chr 5

142945496

142945496

1.39E-55

65.23347

FSCN1

Other

–

Chr 3

41581453

41581453

2.32E-44

64.13043

JADE1

Other

Exon

Chr 9

121792412

121792412

5.80E-53

62.74613

–

Other

Intron

Chr 4

155781218

155781218

4.83E-39

62.30984

TMEM88B

Other

Intron

Chr 6

31666012

31666012

1.21E-81

62.05207

Gm13848

Other

Exon

Chr 18

82756567

82756567

7.26E-80

61.81989

–

Other

Intergenic

Chr 2

30100458

30100458

3.98E-61

−68.875

ZDHHC12

Other

Intron

Chr 2

170791632

170791632

8.07E-49

−67.2973

–

Other

Intron

Chr 10

69846110

69846110

8.28E-53

−66.5238

GM33416

Other

Intron

Chr 9

57968665

57968665

1.39E-36

−63.029

MYO5B

Other

Intron

Chr 4

110051897

110051897

5.55E-47

−62.4214

DMRTA2

Shore

–

Chr 16

97823834

97823834

1.62E-34

−61.5291

–

Other

Intron

Chr 4

134744349

134744349

5.94E-31

−60.3271

LDLRAP1

Other

Exon

Chr 7

36873554

36873554

7.09E-53

−59.9929

–

Other

–

Chr 7

42750002

42750002

3.33E-34

−59.3331

DOCK3

Other

Exon

Chr 5

74960682

74960682

4.97E-51

−59.0323

Gm6116

Other

Intron

Abbreviation: Chr Chromosome

Table 2 Top 10 hypermethylated and hypomethylated regions between HCC and NASH in the choline supplemented model
Chromosome
Hypermethylation

Hypomethylation

Start

End

Q-value

Methylation
difference (%)

Gene

CpG Category

Gene Structure

Chr 10

31860051

31860051

5.08E-36

100

RNF217

Other

Intron

Chr 3

96919939

96919939

6.65E-59

98

GJA8

Other

Exon

Chr 17

54643532

54643532

2.75E-37

97.71429

Gm32055

Other

–

Chr 1

21988549

21988549

3.91E-54

96.51515

KCNQ5

Other

Intron

Chr 5

142385284

142385284

2.78E-42

95.35104

PTPRE

Other

–

Chr 2

123549054

123549054

1.02E-29

95.26627

MORN3

Other

–

Chr 3

55348282

55348282

1.08E-31

93.17359

Gm40051

Other

Intron

Chr 13

51672327

51672327

5.01E-42

91.07143

SECISBP2

Other

Intron

Chr X

60093579

60093579

4.50E-29

90.47619

MCF2

Other

Intron

Chr 16

29868324

29868324

8.94E-38

89.09953

RNF123

Other

–

Chr 5

36228842

36228842

1.50E-57

−87.4512

PSAPL1

Other

Intron

Chr 4

98726981

98726981

1.18E-39

−87.4396

L1TD1

Other

Intron

Chr 4

82537544

82537544

7.33E-64

−87.2659

–

Other

Intron

Chr 7

108951080

108951080

1.18E-26

−86.2069

Gm39067

Island

Intron

Chr 11

82930668

82930668

8.16E-37

−86.1035

UNC45BOS

Shore

Exon

Chr 5

128527390

128527390

1.68E-27

−85.9649

–

Other

–

Chr 5

105759229

105759229

1.97E-27

−84.8837

LRRC8D

Other

Intron

Chr 12

25240371

25240371

6.01E-20

−84.3137

–

Other

Intron

Chr 2

172863024

172863024

6.24E-28

−83.871

–

Other

Intron

Chr 12

36317937

36317937

8.35E-39

−83.8572

SOSTDC1

Shore

Exon

Abbreviation: Chr Chromosome
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Table 3 Top 10 hypermethylated and hypomethylated regions between choline deficient HCC and choline supplemented HCC
Chromosome
Hypermethylation

Hypomethylation

Start

End

Q-value

Methylation
Gene
difference (%)

CpG Category

Gene Structure

Chr 7

27658325

27658325

5.06E-41

68.16218

TTC9B

Island

Exon

Chr 5

110363759

110363759

1.58E-41

57.24965

LCROL1

Island

Exon

Chr 1

42741736

42741736

1.39E-86

56.99229

LOC108167622

Other

Intron

Chr 16

4078449

4078449

8.78E-54

55.9661

TRAP1

Shore

–

Chr 7

107210287

107210287

4.31E-25

54.50725

RBMXL2

Island

Exon

Chr 9

107669835

107669835

3.47E-63

54.2572

SLC38A3

Other

Intron

Chr 19

8679239

8679239

1.30E-35

54.08986

CHRM1

Other

Exon

Chr 4

120124981

120124981

7.45E-29

54.015

EDN2

Other

Exon

Chr 7

107210301

107210301

1.45E-24

53.93071

RBMXL2

Island

Exon

Chr 1

190139252

190139252

8.04E-63

53.61003

PROX1

Other

Intron

Chr 9

121076534

121076534

2.87E-43

−66.7969

OLFR843

Other

Intron

Chr 7

27257369

27257369

6.56E-67

−62.1354

NUMBL

Shore

Exon

Chr 10

76634403

76634403

3.22E-65

−61.6133

–

Other

Intron

Chr 4

45785050

45785050

1.68E-54

−60.7105

ALDH1B1

Other

–

Chr 10

76584578

76584578

4.26E-46

−59.9492

FTCD

Other

Exon

Chr 12

74283740

74283740

5.55E-38

−59.9486

FASTKD2

Shore

Intron

Chr 10

73300112

73300112

2.99E-43

−59.8009

FAM96A

Other

Intron

Chr 9

46986808

46986808

1.95E-46

−59.3403

GM4791

Other

–

Chr 2

44162442

44162442

5.78E-45

−59.2628

ARHGAP15

Other

Intron

Chr 7

37356388

37356388

3.96E-45

−58.4701

–

Other

–

Abbreviation: Chr Chromosome

Table 4 Top statistically significant Gene Ontology molecular functions
Model

Molecular Function

Fold
Enrichment

CD HCC vs. NASH

Hormone binding

3.05

CS HCC vs. NASH

DNA-binding transcription activator activity, RNA polymerase II-specific

1.88

RNA polymerase II cis-regulatory region sequence-specific DNA binding

1.72

Calcium ion binding

1.57

Neuropeptide receptor activity

2.76

Voltage-gated potassium channel activity

2.03

DNA-binding transcription activator activity, RNA polymerase II-specific

1.61

DNA binding transcription repressor activity, RNA polymerase-II specific

1.5

RNA polymerase II cis-regulatory region sequence-specific DNA binding

1.49

Signaling receptor activator activity

1.39

Top statistically significant Gene Ontology molecular functions revealed by enrichment analysis between HCC and NASH in the choline deficient and choline
supplemented mice

methylation of LRRC8D in the context of obesity is consistent with previous studies [16, 18]. Hypermethylation
of MCF2, a proto-oncogene involved in Rho protein signal transduction, was also seen in obese patients with
breast cancer [11, 19].
Comparing HCC in the choline deficient model and
choline supplemented model, significant methylation differences were seen in 11 genes previously associated with

cancer (hypermethylation of TRAP1, SLC38A3, CHRM1,
EDN2, and PROX1; hypomethylation of ALDH1B1,
FTCD, FASTKD2, FAM96A, and ARHGAP15). Of these
genes, four (TRAP1, SLC38A3, PROX1, and FAM96A)
have also been associated with obesity and altered metabolic states, indicating that they may be implicated in differential progression of lean versus obese NASH-HCC
(Fig. 5).

Hymel et al. BMC Cancer

(2022) 22:1276

Page 10 of 13

Table 5 Enriched molecular functions in hypomethylated regions between HCC and NASH
Model

Molecular Function

CD HCC vs. NASH

DNA-binding transcription activator activity, RNA polymerase II-specific

2.14

RNA polymerase II cis-regulatory region sequence-specific DNA binding

1.82

Protein binding

1.17

Wnt-protein binding

4.20

Frizzled binding

3.17

CS HCC vs. NASH

Fold
Enrichment

DNA-binding transcription activator activity, RNA polymerase II-specific

2.21

DNA-binding transcription repressor activity, RNA polymerase II-specific

2.07

RNA polymerase II cis-regulatory region sequence-specific DNA binding

2.00

Receptor ligand activity

1.52

Cation binding

1.18

Top statistically significant Gene Ontology molecular functions revealed by enrichment analysis of hypomethylated regions between HCC and NASH in the choline
deficient and choline supplemented mice

Fig. 5 Summary of differential methylation in the CD and CS models. A summary of the differential methylation patterns between the choline
deficient and choline supplemented models, differentially methylated genes and functions, and potential implications

No overlap exists in the regions with the highest methylation difference between HCC and NASH in the lean
and obese models, indicating that differential methylation

may act through different mechanisms to promote carcinogenesis in the two models. Gene ontology enrichment analysis on the DMRs between HCC and NASH
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in the two models revealed some shared molecular functions, including functions related to gene transcription.
The choline deficient model had DMRs in genes involved
with hormone binding and calcium ion binding, while
the choline supplemented model had DMRs in genes
involved in neuropeptide receptor activity, voltage-gated
potassium channel activity, and signaling receptor activator activity. These signaling pathway molecular functions
may represent potential mechanisms of HCC progression
in the two models. Calcium signaling has previously been
found to be enriched in NAFLD-associated HCC [52].
Looking at the functional enrichment of hypomethylated regions between HCC and NASH, which would
result in overexpression of the associated genes, several important differences were seen between the two
models. In the choline supplemented model, significant
hypomethylation was seen in genes involved in Wntprotein binding and frizzled binding, as well as receptor
ligand activity and cation binding, which were not seen
in the choline deficient model. Additionally, one gene
in Table 2, SOSTDC1, was found to be hypomethylated
(within a CpG shore of an exon); SOSTDC1 is involved in
enhancing Wnt signaling pathways [11].
The Wnt/β-catenin signaling pathway has been implicated in several mechanisms of hepatocarcinogenesis,
including growth, survival, and migration [53]. In the
canonical Wnt signaling pathway, Wnt interacts with
frizzled receptors and activates intracellular signaling
pathways leading to the stabilization of β-catenin, which
can then enter the nucleus and influence transcription
of target genes [54, 55]. β-catenin may regulate the transcription of genes involved in proliferation and metastasis and may also interact with other oncogenic pathways
such as insulin/IFG-1 and H-RAS to influence pathogenesis (Fig. 5) [53, 55]. Mutations in β-catenin have
been found in a large proportion of liver tumors [55].
Additionally, β-catenin has been found to be involved
in changing the tumor-immune microenvironment in
NAFLD-associated HCC [56]. Hypomethylation of genes
involved in Wnt/β-catenin signaling pathways likely contributes to the development and progression of HCC in
the context of obesity. Functional enrichment of Wnt/
β-catenin was not seen in the model of lean NASH-HCC,
indicating that direct involvement of the Wnt signaling
pathways through methylation changes may be unique to
the choline supplemented model. In the choline deficient
model, differential methylation in exons of genes involved
in lipid metabolism (PNPLA6 and LDLRAP1) may alter
signaling pathways leading to the progression of HCC.
Thus, tumor progression may involve lipid metabolism
signaling changes in the lean NASH-HCC model. Differentially methylated regions may be targets for emerging
epigenetic cancer therapeutics; additional work is needed
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to test the study results in humans and examine the effect
of differential methylation on the effectiveness of available therapeutics [57]. Further research is needed to
understand the underlying mechanisms through which
differentially methylated genes drive NASH-HCC development, and progression and to examine differentially
methylated regions in the progression of NASH-HCC in
humans.

Conclusions
A large number of differentially methylated regions are
seen in the progression of NASH-HCC in both lean and
obese mice; differential methylation is also seen between
the stages of progression in the two models. With methylation differences seen in both mice and humans, further studies could be conducted using the obese and lean
mice models to elucidate the mechanisms of progression of NASH-HCC in the context of obesity and normal
weight. Additionally, differentially methylated regions
may be able to serve as biomarkers for cancer progression
or potential therapeutics, highlighting the importance of
the study of epigenetic changes in hepatocarcinogenesis.
Abbreviations
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